EMA Approves Biocon Biologics’ New mAbs Facility in India and Renews GMP Certifications for India and Malaysia Sites

  • Posted by: Biocon Biologics

Biocon Foundation conducts awareness session in 14 Government Schools

  • Posted by: Biocon Biologics

Biocon Biologics Obtains U.S. FDA Approval for Biosimilar Aflibercept for Yesafili™. Enters U.S. Ophthalmology Market

  • Posted by: Biocon Biologics

Biocon Q4FY24 Revenue at Rs 3,966 Cr, EBITDA at Rs 964 Cr; Net Profit (before exceptional items) at Rs 144 Cr

  • Posted by: Biocon Biologics

Biocon Biologics Enters a Long-term Commercial Collaboration with Eris Lifesciences to Expand Patient Access in India

  • Posted by: Biocon Biologics

Biocon Biologics Secures Canada Market Entry Date for YESAFILI®, a Proposed Biosimilar to EYLEA®

  • Posted by: Biocon Biologics

Biocon Biologics Secures US Market Entry Date for Bmab 1200, a Proposed Biosimilar to Stelara®

  • Posted by: Biocon Biologics

Company Statement on rh-Insulin for Veterinary use

  • Posted by: Biocon Biologics

Biocon Included in S&P Global Sustainability Yearbook 2024

  • Posted by: Biocon Biologics

Biocon Biologics Partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab

  • Posted by: Biocon Biologics
Share
buy twitter followers